Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
QuintilesIMS
McKesson
Chinese Patent Office
Cantor Fitzgerald
Cipla
Johnson and Johnson
UBS

Generated: December 15, 2018

DrugPatentWatch Database Preview

Litigation Details for Eisai Co., Ltd. v. Teva Pharm. USA (S.D.N.Y. )

« Back to Dashboard

Small Molecule Drugs cited in Eisai Co., Ltd. v. Teva Pharm. USA
The small molecule drugs covered by the patents cited in this case are ➤ Try a Free Trial , ➤ Try a Free Trial , ➤ Try a Free Trial , and ➤ Try a Free Trial .

Details for Eisai Co., Ltd. v. Teva Pharm. USA (S.D.N.Y. )

Date Filed Document No. Description Snippet Link To Document
2006-10-06 51 of The Patent-in-Suit Eisai, a pharmaceutical company, owns U.S. Patent No. 5,045,552 (“’552 …552 patent”), the patent-in-suit. The ’552 patent claims, among other things, the chemical compound rabeprazole…by their final patent numbers only, as the ’552 patent application and the ’013 patent application respectively…application to issue as patent ’552. (’552 Patent File History, DRLRAB 473.) The patent’s file history does…5,708,013 (“’013 patent”). (‘013 Patent File History, DRLRAB 2281.) The ’013 patent application listed the same External link to document
2006-10-06 52 collectively, “Eisai”), ask that U.S. Patent No. 5,045,552 (“’552 patent”), claiming inter alia the gastric-acid-inhibiting…in this patent-infringement action move for summary judgment of the validity of their patent against …European Patent 174,726, claiming, inter alia, the ulcer-treatment compound lansoprazole (“’726 patent”); …; Junggren’s U.S. Patent No. 4,255,431 (“’431 patent”), claiming, inter alia, the compound omeprazole…the three items cited by Teva, the ’726 patent, the ’431 patent, and the Brandstrom article; and that lansoprazole External link to document
2007-05-11 89 the Junggren patents covering omeprazole, U.S. Patent Nos. 4,337,257, 4,255,431 and 4,508,905. …series of patent applications that ultimately issued as U.S. Patent 5,708,013 (“the ’013 patent”). These…of the Junggren patent, which patent application Eisai had disclosed to the ’552 patent examiner as prior…conduct before the U.S. Patent and Trademark Office (“PTO”) in prosecuting the patent. The case having been… in this action regarding U.S. Patent No. 5,045,552 (“the ’552 patent”). This Court has jurisdiction External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Healthtrust
Express Scripts
Johnson and Johnson
Deloitte
Harvard Business School
AstraZeneca
Fuji
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.